Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
NYSE MKT:ARMP
RESEARCH TOOLSreports
Holding ARMP?
Track your performance easily
ARMP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.93 - $4.48
Previous Close$2.09
Volume686.00
Average Volume (3M)7.50K
Market Cap
$73.01M
Enterprise Value$194.87M
Total Cash (Recent Filing)$17.10M
Total Debt (Recent Filing)$140.33M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Mar 13, 2025EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding36,183,067
10 Day Avg. Volume16,073
30 Day Avg. Volume7,503
Standard Deviation0.31
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-1.48
Price to Sales (P/S)9.34
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue25.40
Enterprise Value/Gross Profit43.03
Enterprise Value/Ebitda-12.15
Forecast
1Y Price Target
$7.00Price Target Upside228.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Armata Pharmaceuticals News
PremiumCompany Announcements
Armata Pharmaceuticals Extends Credit Agreement and CMO Departs
PremiumCompany Announcements
Armata Completes Enrollment for Innovative Bacteriophage Study
PremiumCompany Announcements
Armata Pharmaceuticals VP Richard Rychlik Departs with Benefits
PremiumCompany Announcements
Armata Pharmaceuticals Updates Progress and Corporate Presentation
PremiumCompany Announcements
Armata Pharmaceuticals Welcomes David House as New SVP of FinanceOwnership Overview
0.75% Insiders
1.04% Mutual Funds
0.58% Other Institutional Investors
96.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $1.93 and its highest was $4.48 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 13, 2025 which is in 111 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Nov 13, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.13.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -$0.35.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,183,067 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
---
Armata Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (228.64% Upside)
$7.00 (228.64% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
---
ARMP Stock 12 Month Forecast
Average Price Target
$7.00
▲(228.64% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Bioxcel Therapeutics
―
Oncternal Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering ARMP
1 Year
1 Year Success Rate
11/28 ratings generated profit
1 Year Average Return
-3.61%
reiterated a buy rating 3 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 39.29% of your transactions generating a profit, with an average return of -3.61% per trade.
---